Valuation: EyePoint, Inc.

Market Cap 30.04M 26.9M 24.74M 22.42M 41.91M 2.85B 42.69M 295M 118M 1.5B 113M 110M 4.73B P/E 2026 *
-0.1x
P/E 2027 * -0.18x
Enterprise Value -301M -269M -248M -224M -420M -28.55B -427M -2.95B -1.19B -15.02B -1.13B -1.1B -47.36B EV / Sales 2026 *
-177x
EV / Sales 2027 * -46.7x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day+4.76%
1 week-1.15%
Current month+3.76%
1 month-88.88%
3 months-97.09%
6 months-97.39%
Current year-98.02%
1 week 0.34
Extreme 0.3446
0.42
1 month 0.34
Extreme 0.3446
3.57
Current year 0.34
Extreme 0.3446
18.87
1 year 0.34
Extreme 0.3446
19.11
3 years 0.34
Extreme 0.3446
30.99
5 years 0.34
Extreme 0.3446
30.99
10 years 0.34
Extreme 0.3446
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%-1.15%-97.10%-95.04% 30.04M
-1.17%+10.11%+57.10%+142.72% 1,263B
-1.76%+1.55%+45.19%+80.00% 658B
-2.47%+1.17%+36.86%+102.49% 521B
-1.90%-0.13%+52.60%+66.28% 391B
-1.12%+5.88%+80.48%+44.75% 369B
-1.53%+3.73%+32.90%+56.20% 307B
-1.16%+7.67%+11.94%+33.56% 290B
-0.79%+5.01%+57.57%+75.13% 252B
-1.06%+7.57%+39.86%+110.14% 212B
Average -0.82%+3.92%+31.74%+61.62% 426.2B
Weighted average by Cap. -1.51%+6.60%+48.75%+93.36%

Financials

2026 *2027 *
Net sales 1.7M 1.53M 1.4M 1.27M 2.38M 162M 2.42M 16.73M 6.72M 85.05M 6.39M 6.25M 268M 3.85M 3.45M 3.17M 2.87M 5.37M 365M 5.47M 37.82M 15.18M 192M 14.45M 14.14M 606M
Net income -325M -291M -268M -243M -454M -30.88B -462M -3.19B -1.28B -16.24B -1.22B -1.19B -51.23B -198M -178M -163M -148M -277M -18.82B -282M -1.95B -782M -9.9B -744M -728M -31.23B
Net Debt -331M -296M -272M -247M -461M -31.4B -470M -3.25B -1.3B -16.52B -1.24B -1.21B -52.09B -210M -188M -173M -157M -293M -19.92B -298M -2.06B -827M -10.48B -787M -771M -33.05B
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
03/11/26 USD 0.3624 +4.02% 408,479
30/10/26 USD 0.3484 -8.32% 6,119,164
29/10/26 USD 0.3800 +0.69% 6,601,723
28/10/26 USD 0.3774 +3.91% 6,504,012
27/10/26 USD 0.3632 -0.68% 9,675,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.3484USD
Average target price
8.438USD
Spread / Average Target
+2,321.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EyePoint, Inc.
  1. Stock Market
  2. Stocks
  3. EYPT Stock